• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Johnson & Johnson

    6/23/25 9:42:57 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JNJ alert in real time by email
    11-K 1 a2024form11-kxjjretirement.htm 11-K Document


     UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

    FORM 11-K

    FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS
    AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934
    ------------------------------

    [X] ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the Fiscal Year Ended December 31, 2024
    OR
    [ ] TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    Commission File Number  1-3215
    ------------------------------
    JOHNSON & JOHNSON
    RETIREMENT SAVINGS PLAN

    (Full title of the Plan)

    JOHNSON & JOHNSON
    ONE JOHNSON & JOHNSON PLAZA
    NEW BRUNSWICK, NEW JERSEY 08933

    (Name of issuer of the securities held pursuant to the Plan
    and the address of its principal executive office)







    REQUIRED INFORMATION

    Item 4.   Financial Statements and Supplemental Schedule

    Financial statements prepared in accordance with the financial reporting requirements of ERISA filed herewith are listed below in lieu of the requirements of Items 1 to 3.

    Report of Independent Registered Public Accounting Firm

    Financial Statements:

    Statements of Net Assets Available for Benefits

    Statement of Changes in Net Assets Available for Benefits

    Notes to Financial Statements

    Supplemental Schedule*:

    Schedule H, line 4i - Schedule of Assets (Held at End of Year)



    Signatures

    *Other supplemental schedules required by Section 2520.103-10 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 (“ERISA”), as amended, have been omitted because they are not required or are not applicable.

    Exhibits:
    23.  Consent of PricewaterhouseCoopers LLP, dated June 23, 2025





    SIGNATURES


    The Plan.   Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.



    JOHNSON & JOHNSON RETIREMENT SAVINGS PLAN
    Date: June 23, 2025
    By:
    /s/ Kristen Mulholland
    Kristen Mulholland
    Chairman, Pension and Benefits Committee














    JOHNSON & JOHNSON RETIREMENT SAVINGS PLAN
    __________________


    FINANCIAL STATEMENTS AND
    SUPPLEMENTAL SCHEDULE


    DECEMBER 31, 2024 AND 2023




    Johnson & Johnson Retirement Savings Plan
    Index to Financial Statements and Supplemental Schedule





    Page(s)
    Report of Independent Registered Public Accounting Firm
    1
    Financial Statements:
    Statements of Net Assets Available for Benefits
    2
    Statement of Changes in Net Assets Available for Benefits
    3
    Notes to Financial Statements
    4-15
    Supplemental Schedule*:
    Schedule H, line 4i - Schedule of Assets (Held at End of Year)
    16
    *Other supplemental schedules required by Section 2520.103-10 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974 (“ERISA”), as amended, have been omitted because they are not required or are not applicable.




    Report of Independent Registered Public Accounting Firm

    To the Administrator and Plan Participants of Johnson & Johnson Retirement Savings Plan

    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for benefits of Johnson & Johnson Retirement Savings Plan (the “Plan”) as of December 31, 2024 and 2023 and the related statement of changes in net assets available for benefits for the year ended December 31, 2024, including the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024 in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Information

    The supplemental Schedule H, line 4i - Schedule of Assets (Held at End of Year) as of December 31, 2024 has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental schedule is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental schedule reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedule. In forming our opinion on the supplemental schedule, we evaluated whether the supplemental schedule, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental schedule is fairly stated, in all material respects, in relation to the financial statements as a whole.

    /s/ PricewaterhouseCoopers LLP
    New York, New York
    June 23, 2025

    We have served as the Plan’s auditor since 1991.

    1

    Johnson & Johnson Retirement Savings Plan
    Statements of Net Assets Available for Benefits



    December 31
    20242023
    Assets
    Interest in Johnson & Johnson Pension and Savings Plans Master Trust,
    at fair value
    $540,439,280 $499,790,719 
    Total investments540,439,280 499,790,719 
    Receivables
    Employee contributions— 182,729 
    Employer contributions
    — 55,586 
    Notes receivable from participants1,524 1,524 
    Total receivables
    1,524 239,839 
                     Other assets52,143 23,992 
    Total assets
    540,492,947 500,054,550 
    Net assets available for benefits
    $540,492,947 $500,054,550 
    The accompanying notes are an integral part of these financial statements.
    2

    Johnson & Johnson Retirement Savings Plan
    Statement of Changes in Net Assets Available for Benefits





    Year Ended
    December 31,
    Additions to net assets attributed to2024
    Investment Income/Loss
    Plan's interest in the Johnson & Johnson Pension and Savings Plans Master Trust net
    investment income/loss
    $39,941,108 
    Contributions
    Employee contributions
    24,940,213 
    Employer contributions7,866,275 
    Total additions
    72,747,596 
    Deductions from net assets attributed to
    Benefits paid to participants
    31,277,087 
    Administrative expenses1,032,112 
    Total deductions
    32,309,199 
    Net increase/(decrease)40,438,397 
    Net assets available for benefits
    Beginning of year500,054,550 
             End of year $540,492,947 
    The accompanying notes are an integral part of these financial statements.
    3

    Johnson & Johnson Retirement Savings Plan
    Notes to Financial Statements

    1.    Description of the Plan
    General
    The Johnson & Johnson Retirement Savings Plan (the “Plan”) is a participant directed defined contribution plan which was established on March 1, 1990 for eligible employees of certain participating subsidiaries of Johnson & Johnson ("Johnson & Johnson" or the “Company”) located in Puerto Rico which have adopted the Plan. The Plan was designed to provide eligible employees with an opportunity to strengthen their financial security at retirement by providing an incentive to save and invest regularly. The Plan is administered by the Pension & Benefits Committee (the "Plan Administrator") of Johnson & Johnson. The funding of the Plan is made through employee and Company contributions. The net assets of the Plan are held in the Johnson & Johnson Pension and Savings Plans Master Trust (the “Trust”). Recordkeeping services are provided by Alight Solutions. The Plan’s interest in the Trust is allocated to the Plan based upon the total of each participant’s share of the Trust.
    State Street Bank and Trust Company (“State Street” or "Custodian") serves as agent and custodian of the Plan for purposes of investment of the assets of the Trust. Banco Popular de Puerto Rico serves as Trustee of the Plan. As such, State Street performs certain services for the Plan, including the execution of certain participant directed investments, which are commingled for investment purposes only with assets of other tax-qualified plans maintained by Johnson & Johnson.
    This brief description of the Plan is provided for general information purposes only. Participants should refer to the Plan document for complete information.
    Contributions
    In general, salaried and hourly employees of participating Johnson & Johnson companies who are Puerto Rico residents can contribute to the Plan immediately. There is no service requirement for employee contributions.

    If a participant does not take action to enroll or declines enrollment in the Plan within their first 30 days of employment, they will be automatically enrolled for pre-tax employee contributions equal to 3% of their eligible pay and these contributions will be invested in the Plan's default investment option. The Plan's default investment option is the Target Retirement Fund that aligns with, or is closest to, the year in which the participant will turn age 62.
    Contributions are made to the Plan by participants through payroll deductions and by the Company on behalf of the participants.  Participating employees may contribute a minimum of 3% up to a maximum of 25% pre-tax and/or a minimum of 1% up to a maximum of 10% post-tax of their base salary.  Annual pre-tax contributions may not individually exceed $15,000 in 2024 under Puerto Rico law.
    Participants age 50 and over are eligible to contribute extra pre-tax contributions (“catch-up contributions”) above the annual Puerto Rico Internal Revenue Code of 2011 (the "PR Code") limitation up to $1,500 in 2024. Participants can elect an amount to be contributed from each paycheck as their catch-up contribution.  This amount will be in addition to the pre-tax contribution percentages that participants have elected. The catch-up contribution is not eligible for the Company matching contribution.
    After one year of service, participants receive a Company matching contribution equal to 75% of the first 6% of his/her pretax contributions. The Company matching contribution is comprised of cash and invested in the current investment fund mix chosen by the participant.
    Investments
    Participants may invest in one or more of the various investment funds offered by the Plan.  The Plan made the following changes to the investment line up in 2024. On July 1, 2024 the Plan introduced the U.S. Bond Index Fund and the International Equity Index Fund and on December 30, 2024 the Plan merged the Target Retirement 2025 Fund into the Target Retirement Fund. Each of the Plan's funds represents a mix of various investments. The investment mix chosen by the participant will apply to employee and Company matching contributions.  Rollover contributions are invested at the election of the participant.
    Participants receive dividends on Johnson & Johnson common stock shares held in the Johnson & Johnson Common Stock Fund.  The dividends are automatically reinvested in the Johnson & Johnson Common Stock Fund. For all other funds, State Street reinvests all dividend and interest income.
    4

    Johnson & Johnson Retirement Savings Plan
    Notes to Financial Statements

    Effective September 1, 2020, participants are not permitted to (1) direct more than 20% of any contribution made to the Plan to the Johnson & Johnson Common Stock Fund or (2) transfer or reallocate amounts into the Johnson & Johnson Common Stock Fund if, immediately after such transfer or reallocation, the aggregate value of their investments in the Johnson & Johnson Common Stock Fund would exceed 20% of their aggregate Plan Balance. This limitation does not (a) affect investments resulting from transfers before September 1, 2020 or (b) restrict percentages in excess of 20% that result from investment performance or reinvestment of dividends.
    Vesting
    A participant’s interest in his/her account, including participant contributions, Company contributions and earnings thereon, is always fully vested.  As a result, there are no forfeitures under the Plan.

    Payment of Benefits
    Participants are allowed to withdraw their post-tax contributions and earnings thereon one time per calendar year. Participants may withdraw pre-tax contributions only upon meeting certain hardship conditions.  The benefits to which participants are entitled are the amounts provided by contributions (Company and participant) and investment earnings thereon, including net realized and unrealized gains and losses which have been allocated to the participant’s account balance. Participants have the option of receiving part of their balance in the Johnson & Johnson Common Stock Fund as either cash or in shares of Johnson & Johnson common stock (plus cash for fractional shares) for lump sum distributions other than a hardship.
    Benefits are also paid to participants upon termination of employment, long-term disability or retirement.  Participants can elect to defer payment if account balances are greater than $5,000.  Distributions are paid either in a lump sum payment, or installment payments made on a monthly, quarterly or annual basis over a period of years selected by the participant.
    A participant’s account may be distributed to his/her beneficiaries in lump sum or in installments upon the participant’s death only if the beneficiary is a spouse. Otherwise, it is paid to the beneficiary in a lump sum, either directly or rolled over to an Individual Retirement Account ("IRA").
    Administrative Expenses
    To cover recordkeeping expenses for the Plan, each participant is charged an annual administration fee of $36, which is assessed on a monthly basis. All other third-party administrative expenses are paid by the Plan, unless otherwise provided for by the Company.

    Notes Receivable from Participants
    Participants are not permitted to take loans from the Plan. However, due to an acquisition, there are existing loans which must be allowed to continue once rolled into the Johnson & Johnson Retirement Savings Plan. The collateralized balances in the participant’s accounts have interest rates of 3.25%.  Principal and interest is paid ratably through payroll deductions for active employees.  Loans must be paid within two months following retirement or termination of employment with the Company. If the loan is not repaid in full, the unpaid balance, plus accrued interest, will be deducted from the participant’s account balance and reported as a distribution.
    Termination
    Although it has not expressed an intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA.  In the event of a partial or full Plan termination, all Plan funds must be used exclusively for the benefit of the Plan participants, in that each participant would receive the respective value in their account.
    2. Summary of Significant Accounting Policies
        Basis of Accounting
    The financial statements of the Plan are prepared under the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America.



    5

    Johnson & Johnson Retirement Savings Plan
    Notes to Financial Statements

    Investment Valuation and Income Recognition of the Trust
    The Plan’s interest in the Trust is stated at fair value, except for the fully benefit-responsive investment contracts which are stated at contract value. The investment in the Trust represents the Plan's interest in the net assets of the Trust.
    As the investment funds contain various underlying assets such as stocks and short-term investments, the participant’s account balance is reported in units of participation, which allows for immediate transfers in and out of the funds.  The purchase or redemption price of the units is determined by the Trustee, based on the current market value of the underlying assets of the funds.  Each fund’s net asset value for a single unit is computed by adding the value of the fund’s investments, cash and other assets, and subtracting liabilities, then dividing the result by the number of units outstanding.
    Purchases and sales of securities are recorded on a trade-date basis.  Gains and losses on the sale of investments are determined on the average cost method.  Dividend income is recorded on the ex-dividend date. Interest income and administrative expenses are recorded on an accrual basis.
    The Plan presents, in the Statement of Changes in Net Assets Available for Benefits, the net investment income/loss for the Plan's interest in the Trust which consists of the Plan’s allocated change in unrealized appreciation and depreciation of the underlying investments, realized gains and losses on sales of investments and investment income/loss based upon the total of each participant's share of the Trust.
    Payment of Benefits
    Benefit payments to participants are recorded upon distribution.
    Derivatives
    The Trust mitigates risk through structured trading with reputable parties and continual monitoring procedures. The Trust enters into forward foreign exchange contracts to hedge against adverse changes in foreign exchange rates related to non-U.S. dollar denominated investments. The Trust is exposed to credit risk for non-performance by the counterparty and to market risk for changes in interest and currency rates. The Trust accounts for forward foreign exchange contracts at fair value.

    The fair value of a forward foreign exchange contract is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate.

    The Trust actively manages risk by periodically investing in interest rate swaps, credit default swaps and fixed income options. Interest rate swaps are used to manage interest rate risk and provide an effective means to adjust portfolio duration, maturity mix and term-structure. Credit default swaps are used to either synthetically add or reduce credit risk to an individual issuer or a basket of issuers. Depending on the type of contract, the counterparty risk exposure can be either with the exchange or another counterparty. Fixed income options are used in various ways including: to pursue upside exposure to a portion of the yield curve, to capitalize on anticipated changes in market volatility, to focus on generating income, and to serve as a hedge. The Trust records interest rate swaps, credit default swaps and options at fair value. Interest rate swaps are valued daily using underlying yield curves based upon broker/dealer sources, the present value of expected cash flows, and frequency of which they compound and pay. Credit default swaps are valued using daily underlying yield curves and/or credit curves and spreads based upon broker/dealer/index sources, the present value of expected cash flows, and the frequency of which they compound and pay including a weighted default calculation. Options are fair valued using market-based inputs to models, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency, where such inputs and models are available. Alternatively, the values may be obtained through unobservable management determined inputs and/or management’s proprietary models. Where models are used, the selection of a particular model to value an option depends upon the contractual terms of, and specific risks inherent in, the option as well as the availability of pricing information in the market. Valuation models require a variety of inputs, including contractual terms, market prices, measures of volatility and correlations of such inputs.
    The Trust may also enter into total return swap contracts, which are contracts in which one party agrees to make periodic payments based on the change in market value of the underlying assets, which may include a specified security, basket of securities or security indexes during the specified period, in return for periodic payments based on a fixed or variable interest rate of the total return from other underlying assets. Total return swap agreements may be used to obtain exposure to a security or market without owning or taking physical custody of such security or market. Total return swaps involve not only the risk associated with the investment in the underlying securities, but also the risk of the counterparty not fulfilling its obligations under the agreement. Total return swaps are valued daily using underlying index levels for fixed and financing legs. The Trust determines the fair value of total return swaps based on published index prices. The total market value is the sum of the market value of both the fixed and the float legs. The market value of the fixed leg is determined by the change in price of the asset times the units. The market value of the float leg is determined by the accrued financing given the reset frequency and financing index. The Mark-to-Market (MTM) / swap value is collateralized daily.

    A futures contract is an agreement to buy or sell a security or other asset for a set price on a future date. These contracts are traded on major exchanges and are marked to market daily, thus minimizing counterparty risk. The Trust enters into futures contracts mainly to manage the duration and refine the curve positioning of the fixed income portfolios, thus, allowing the investment managers to achieve the overall investment portfolios' objectives. These contracts are traded on the exchange and the fair value is the daily mark to market, which is a function of price movements for the contract relative to the level it was originally entered into.
    There have been no changes in the methodologies used at December 31, 2024 and 2023.
    Use of Estimates
    The preparation of the Plan’s financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of Net Assets Available for Benefits at the date of the financial statements and the Changes in Net Assets Available for Benefits during the reporting period and the applicable disclosures of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates.
    Risks and Uncertainties
    The Plan provides for various investment options in funds which can invest in a combination of equity, fixed income securities and other investments. Investments are exposed to various risks, such as interest rate, market and credit.  Due to the level of risk associated with certain investments, it is at least reasonably possible that changes in risks in the near term could materially affect participants’ account balances and the amounts reported in the Statements of Net Assets Available for Benefits and the Statement of Changes in Net Assets Available for Benefits.


    Reporting of Fully Benefit-Responsive Investment Contracts
    Fully benefit-responsive investment contracts are reported at contract value. Contract value is the relevant measurement criteria for that portion of the net assets available for benefits of a defined contribution plan attributable to fully benefit-responsive investment contracts because contract value is the amount participants would receive if they were to initiate permitted transactions under the terms of the Plan.
    3.    Johnson & Johnson Pension and Savings Plans Master Trust
    The assets of the Johnson & Johnson Savings Plan, the Johnson & Johnson Retirement Savings Plan, the Retirement Plan of Johnson & Johnson and Affiliated Companies, the Johnson & Johnson Retirement Plan for Union Represented Employees, and the Johnson & Johnson Retirement Plan for Puerto Rico Employees comprise the total of the Trust which is held by State Street.




    6

    Johnson & Johnson Retirement Savings Plan
    Notes to Financial Statements

    The following table presents the net assets of the Master Trust and the Plan's interest in the net assets of the Master Trust as of December 31, 2024 and 2023.
    Retirement Savings
    Master TrustPlan's Interest in Master Trust
    2024202320242023
    ASSETS
    Investments, at fair value
    Short-term investment funds$1,250,144,436 $1,414,552,462 $20,725,172 $18,872,648 
    Government and agency securities6,702,640,214 4,542,366,717 10,222,430 12,726,374 
    Debt Securities2,655,972,031 4,392,875,028 8,003,252 10,522,330 
    Equity Securities15,780,859,727 16,261,263,935 249,370,553 256,925,507 
    Common collective trusts14,649,283,090 13,461,032,289 191,321,884 141,370,843 
    Limited Partnerships/Co-Investments3,623,532,368 2,902,977,002 1,329,496 1,125,649 
    Other assets and liabilities, net(101,772,978)(24,110,909)89,514 24,207 
    Total Investments at Fair Value$44,560,658,888 $42,950,956,524 $481,062,301 $441,567,558 
    Other assets
    Guaranteed and synthetic investment
       contracts at contract value$1,768,181,421 $2,019,631,434 $60,070,908 $58,842,174 
    Receivable for investments sold409,180,700 330,099,227 718,043 869,562 
    Interest receivables76,491,082 79,848,475 156,444 171,504 
    Dividend receivables8,237,777 7,728,539 78,374 74,162 
    Other receivables9,170,067 14,106,414 110,394 116,281 
    Total Other Assets$2,271,261,047 $2,451,414,089 $61,134,163 $60,073,683 
    Total Master Trust assets$46,831,919,935 $45,402,370,613 $542,196,464 $501,641,241 
    LIABILITIES
    Payables for investments purchased$(578,825,229)$(426,550,413)$(1,544,643)$(1,688,988)
    All other payables(62,778,061)(34,235,785)(212,541)(161,534)
    Total Liabilities$(641,603,290)$(460,786,198)$(1,757,184)$(1,850,522)
    Net Master Trust assets$46,190,316,645 $44,941,584,415 $540,439,280 $499,790,719 


    The following table presents the changes in net assets for the Master Trust for the year ended December 31, 2024
    2024
    Changes in Net Assets:
      Net appreciation (depreciation) in fair value of investments $3,161,323,142 
       Interest413,951,763 
       Dividends288,162,648 
            Total net investment income (loss)3,863,437,553 


    a.     Fair Value Measurements
    The Plan’s valuation methodologies were applied to all of the Trust's investments carried at fair value. Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.
    7

    Johnson & Johnson Retirement Savings Plan
    Notes to Financial Statements

    While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.
    Valuation Hierarchy
    FASB Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures, provides the framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under FASB ASC 820 are described as follows:
    •Level 1 - Quoted prices in active markets for identical assets and liabilities.
    •Level 2 - Significant other observable inputs.
    •Level 3 - Significant unobservable inputs.
    A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
    The following is a description of the valuation methodologies used for the investments measured at fair value:
    •Short-term investment funds - The assets are generally comprised of cash and quoted short-term instruments which are valued at the closing price or the amount held on deposit by the custodian bank where quoted prices are available in an active market and are classified as Level 1.  Other investments are through investment vehicles valued using the Net Asset Value ("NAV") provided by the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The NAV is a quoted price in a market that is not active and classified as Level 2. If NAV is quoted in an active market, the investment would be classified as Level 1.
    •Government and agency securities - The assets are comprised of government and agency securities and U.S. Treasury bills and notes of varying maturities. These are all generally classified as Level 2 fair values which are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows.
    •Government and agency securities include reverse repurchase agreements. A reverse repurchase agreement, commonly known as a reverse repo, is a financial transaction where one party purchases securities from another party with a simultaneous agreement to sell them back at a later date. The price agreed upon for the repurchase is typically higher than the original sale price, reflecting an implicit interest rate known as the repo rate. Reverse repos are widely used in financial markets for liquidity management, collateralized borrowing, and short-term investment strategies. Repurchase agreements are valued based on expected settlement per the contract terms. The amounts of Reverse Repos were ($1,139,063,013) and ($1,084,810,231) in 2024 and 2023, respectively.
    •Debt instruments - The assets are comprised of corporate debt and commercial loans and mortgages. Fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are generally classified as Level 2. Level 3 debt instruments are priced based on unobservable inputs.
    •Equity securities - U.S. and International equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level 1 of the valuation hierarchy.
    •Other assets and liabilities, net - Derivatives, and related cash and securities collateral, as applicable, are included in this category. In general, derivatives that are exchange listed and actively traded are classified as Level 1, while derivatives that are not exchange listed but still actively traded in observable markets are classified as Level 2.
    •Common Collective Trusts (CCT's) - The fair value of all CCT interests have been determined using NAV as a practical expedient. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. The CCT's are included in Investments measured at Net Asset Value. A majority of the CCT's are used for liquidity purposes for both the defined benefit and defined contribution plans within the Trust. The CCTs are primarily passive funds that provide daily liquidity with no prior notice for participant transactions, and 2-day prior notice for Plan Sponsor transactions for the various Plan investment options. Participant directed purchases and sales are transacted at the NAV.  At December 31, 2024 and 2023, approximately 69% and 69%, respectively, of the CCT's are invested in passive strategies that mimic the indices, and 31% and 31%, respectively, in active strategies.  Additionally, at December 31, 2024 and 2023, 61% and 63%, respectively, of the active and passive CCT's are invested in U.S. equities, 26% and 26%, respectively, are invested in global equities and emerging markets, and the remaining 13% and 11%, respectively, are invested in fixed income.  There are no unfunded commitments for any of the CCT's that the Trust invests in.
    •Limited Partnerships ("LP") - The Trust invests in LP investments including Emerging Market Long-Only Equity Funds and Private Market Funds. As of December 31, 2024 and 2023, approximately 3% and 5%, respectively, of these investments are invested in Emerging Market Long-Only Equity Funds and 97% and 95%, respectively, in Private Market Funds.
    The Trust's private market program has invested as a limited partner in a well-diversified portfolio of funds managed by general partners. The program is being managed to ensure adequate diversification by general partner, strategy type (private equity, real assets, and private credit), and geographic region. The Trust engages in co-investments alongside the general partners of the funds, as presented by them, to access attractive investments beyond the pro rata interest obtained through the fund investments. The Trust employs diverse valuation methodologies for co-investments, including multiples of earnings, discounted cash-flow analysis, and fundamental investment assessment. Factors such as financial statements, purchase price, and market observations are considered to ensure a comprehensive and accurate determination of fair value. The Trust will also assess NAV calculations from the General Partners following a similar valuation methodology. As of December 31, 2024 and 2023, approximately 58% and 56%, respectively, of these investments are invested in private equity (as of December 31, 2024 and 2023 Co-investments represent 17% and 13%, respectively, of the private equity strategy), 15% and 16%, respectively, in real assets, and 27% and 28%, respectively, in private credit. The Trust has entered into a number of private markets agreements that commit the Trust, upon request, to make additional investment purchases up to predetermined amounts. As of December 31, 2024, and 2023, the Trust had aggregate unfunded commitments of $2,032,793,729 and $2,075,841,155 respectively. These commitments are expected to be satisfied with distributions from existing funds, reinvestment of proceeds and/or periodic rebalancing of existing investments. The LP investments have target maturity dates ranging from 2025 to at least 2035 with the possibility of 2 to 4 years of extensions in accordance with the respective LP's governing documents. Distributions to the Trust from LP investments are generally driven by portfolio company liquidation in the public and private markets or other events. Otherwise, the LP investments are not redeemable. The fair value of the Trust's LP investments, excluding co-investments, has been determined using NAV provided by the respective general partners as a practical expedient. The NAV is the pro-rata share of the Trust's position based on the value of the underlying assets owned by the LP, minus its liabilities.
    2024 Master Trust Investments Measured at Fair Value
    Quoted market
    prices inputs
    Observable
    inputs
    Unobservable
    inputs
    Investments measured at Net Total Assets
    December 31, 2024(Level 1)(Level 2)
    (Level 3)
    Asset Value
    Short-term investment funds$— $1,250,144,436 $— $— $1,250,144,436 
    Government and agency securities— 6,702,640,214 — — 6,702,640,214 
    Debt instruments— 2,655,972,031 — — 2,655,972,031 
    Equity Securities15,780,859,727 — — — 15,780,859,727 
    Common collective trusts— — — 14,649,283,090 14,649,283,090 
    Limited Partnerships/Co-Investments— — 96,720,580 3,526,811,788 3,623,532,368 
    Other assets and liabilities, net(113,770,373)11,997,395 — — (101,772,978)
    Trust investments at fair value$15,667,089,354 $10,620,754,076 $96,720,580 $18,176,094,878 $44,560,658,888 
    8

    Johnson & Johnson Retirement Savings Plan
    Notes to Financial Statements

    2023 Master Trust Investments Measured at Fair Value
    Quoted market
    prices inputs
    Observable
    inputs
    Unobservable
    inputs
    Investments measured at Net Total Assets
    December 31, 2023(Level 1)(Level 2)(Level 3) Asset Value
    Short-term investment funds$— $1,414,552,462 $— $— $1,414,552,462 
    Government and agency securities— 4,542,366,717 — — 4,542,366,717 
    Debt instruments— 4,392,875,028 — — 4,392,875,028 
    Equity securities16,261,263,935 — — — 16,261,263,935 
    Common Collective Trusts— — 13,461,032,289 13,461,032,289 
    Limited Partnerships/Co-Investments— — 84,317,812 2,818,659,190 2,902,977,002 
    Other assets and liabilities, net(88,109,350)63,998,441 — — (24,110,909)
    Trust investments at fair value$16,173,154,585 $10,413,792,648 $84,317,812 $16,279,691,479 $42,950,956,524 

        
    b.    Synthetic Investment Contracts
    The Trust holds investments in synthetic GICs.  The weighted average insurance financial strength rating of the insurers for these contracts is Aa3.  These investments are recorded at their book values. The synthetic GICs’ contract value represents book value plus reinvested income adjusted for net cash flows. The synthetic GICs are fully benefit-responsive. Participants may under most circumstances direct the withdrawal or transfer of all or a portion of their investment at contract value. Currently no reserves are needed against contract values for credit risk of the contract issuers or otherwise.
    The synthetic GICs provide a return over a period of time through a fully benefit-responsive contract, or wrapper contract, which is backed by the underlying assets owned by the Trust.  The portfolio of assets with overall Aa2/AA credit quality, underlying the synthetic GICs primarily includes government and agency securities, corporate debt, mortgage backed securities, and asset backed securities. The contract value of the synthetic GICs was $1,768,181,421 and $2,019,631,434 at December 31, 2024 and December 31, 2023, respectively.
    There are certain events not initiated by Plan participants that limit the ability of the Plan to transact with the issuer of a GIC (synthetic or traditional) at its contract value. Specific coverage provided by each synthetic GIC may be different from each issuer. Examples of such events include:  the Plan’s failure to qualify under the Internal Revenue Code ("IRC") of 1986 as amended; full or partial termination of the Plan; involuntary termination of employment as a result of a corporate merger, divestiture, spin-off, or other significant business restructuring, which may include early retirement incentive programs or bankruptcy; changes to the administration of the Plan which decreases employee or employer contributions, the establishment of a competing plan by the plan sponsor, the introduction of a competing investment option, or other Plan amendment that has not been approved by the contract issuers; dissemination of a participant communication that is designed to induce participants to transfer assets from this investment option; events resulting in a material and adverse financial impact on the contract issuer, including changes in the tax code, laws or regulations.  The Plan fiduciaries believe that the occurrence of any of the aforementioned events, which would limit the Plan’s ability to transact with the issuer of a GIC at its contract value, is not probable.
    c.     Derivatives
    Presented in the following table is the fair value of derivatives within the Trust as of December 31, 2024 and 2023. The net unrealized appreciation/depreciation of these derivative instruments is included in the Interest in Johnson & Johnson Pension and Savings Plans Master Trust, at fair value in the Statements of Net Assets Available for Benefits. Derivatives are included in the Other assets and liabilities, net category in the Master Trust Table.
    9

    Johnson & Johnson Retirement Savings Plan
    Notes to Financial Statements

    20242023
    AssetLiabilityAssetLiability
    Fair Value of Derivatives
    Forward Foreign Exchange Contracts$67,841 $— $— $526 
    Futures— 4,059,383 — 1,226,065 
    Interest Rate Swaps43,615 — 6,273,595 — 
    Credit Default Swaps— 3,726,186 — 136,198 
    Options— 22,416 — — 
    Total Return Swaps— 33,848,570 103,555,961 — 
    Total$111,456 $41,656,555 $109,829,556 $1,362,789 

    The following table provides information on the investment gains/(losses) on derivatives within the Trust for the year ended December 31, 2024. These amounts are included in the Plan’s interest in the Johnson & Johnson Pension and Savings Plans Master Trust net investment income/loss on the Statement of Changes in Net Assets Available for Benefits.
    2024
    Realized (Loss)/GainChange in Unrealized (Loss)/GainTotal Investment (Loss)/Gain
    Forward Foreign Exchange Contracts$256,072 $68,367 $324,439 
    Futures(30,123,415)(2,833,318)(32,956,733)
    Interest Rate Swaps2,488,419 (6,229,980)(3,741,561)
    Credit Default Swaps838,319 (3,589,988)(2,751,669)
    Options— (22,416)(22,416)
    Total Return Swaps86,281,771 (137,404,531)(51,122,760)
    Total$59,741,166 $(150,011,866)$(90,270,700)

    The following table provides information on collateral pledged by and owed to the Trust as of December 31, 2024 and 2023.
    20242023
    Pledged/ (Owed)Pledged/ (Owed)
    CashCash
    Futures— 607,000 
    Swaps(9,440,000)(109,698,750)


    10

    Johnson & Johnson Retirement Savings Plan
    Notes to Financial Statements

    The following table provides the average notional value of derivatives held by the Trust as of December 31, 2024 and 2023.
    Average Notional Value
    20242023
    Purchased Forward Foreign Exchange Contracts$2,327,990 $7,680,808 
    Sold Forward Foreign Exchange Contracts10,323,692 63,435,902 
    Purchased Futures Contracts2,415,846,358 1,087,807,083 
    Sold Futures Contracts39,707,608 23,234,604 
    Purchased Options Contracts250,000 2,333,333 
    Written Options Contracts6,800,000 20,050,000 
    Interest Rate Swaps602,893,898 417,187,539 
    Written Credit Default Swaps182,271,163 230,954,848 
    Total Return Swaps1,755,247,963 1,115,293,666 
    For the written credit default swaps, the recourse provisions are determined either by the International Swaps and Derivatives Association ("ISDA") agreements or the exchange. Where the Trust is a seller of credit default swaps and if a credit event occurs due to the default of the underlying security or the underlying tranche, this would result in a net loss to the Trust. At December 31, 2024, the maximum payout for outstanding credit default swaps aggregated to $162,305,000 with terms as follows:
    December 31, 2024
    Number of ContractsMaturityTotal Value
    41 Year$5,600,000 
    92 Years110,930,000 
    43 Years8,275,000 
    14 Years200,000 
    35 Years10,700,000 
    27 Years9,200,000 
    28 Years8,100,000 
    29 Years1,300,000 
    110 Years8,000,000 

        At December 31, 2023, the maximum payout for outstanding credit default swaps aggregated to $220,985,000
    with terms as follows:

    December 31, 2023
    Number of ContractsMaturityTotal Value
    21 Year$400,000 
    42 Years5,600,000 
    123 Years119,650,000 
    64 Years9,235,000 
    45 Years58,900,000 
    28 Years9,200,000 
    29 Years8,100,000 
    110 Years9,900,000 
    4.    Notes Receivable from Participants
    The Plan had participant loans outstanding at December 31, 2024 and December 31, 2023 of $1,524 and $1,524, respectively. Delinquent notes receivable from participants are reclassified to benefit payments based on terms of the Plan document.
    11

    Johnson & Johnson Retirement Savings Plan
    Notes to Financial Statements

    5.     Tax Status
    The Plan received a favorable determination letter from the PR Treasury under the PR Code dated June 21, 2018. Although the Plan has been amended since receiving the determination letter, the Plan Administrator believes that the Plan is currently designed and is currently being operated in compliance with the applicable requirements of the PR Code. The Trust associated with the Plan is intended to be exempt from Puerto Rico income taxation pursuant to the provisions of Section 1081.01(a) of the PR Code, and, pursuant to Section 1022(i)(1) of ERISA, for United States income tax purposes, the Plan's Master Trust is intended to be considered as an organization as described in Section 401(a) of the U.S. Internal Revenue Code of 1986, as amended (the "U.S. Code") and exempt under Section 501(a) of the U.S. Code. Accordingly, no provision for income taxes has been made.

    Accounting principles generally accepted in the United States of America require plan management to evaluate tax positions taken by the Plan and recognize a tax liability (or asset) if the Plan has taken an uncertain tax position that more likely than not would not be sustained upon examination by the PR Treasury pursuant to the provisions of the PR Code, as appropriate.  The Plan Administrator has concluded that as of December 31, 2024 and December 31, 2023, there are no uncertain tax positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.
    6.    Related Party Transactions
    Certain Plan investments, such as shares of CCT's managed by State Street Global Advisors, a division of State Street and shares of State Street common stock and bonds, qualify as party-in interest transactions as State Street is the custodian as defined by the Plan. As of December 31, 2024 and December 31, 2023, the total market value of investments in these interests allocated to the Plan and managed by State Street was $188,482,362 and $143,410,325, respectively.
    The Plan also invests in shares of the Company.  The Company is the Plan sponsor and, therefore, these transactions qualify as party-in-interest transactions. As of December 31, 2024 and December 31, 2023, the fair value of investments in Johnson & Johnson common stock was $128,695,603 and $148,548,454, respectively. During the year ended December 31, 2024, the Plan made purchases of $4,487,962 and sales of $13,733,392 of the Company’s common stock. The total dividend income received during 2024 was $4,482,572. The total realized and unrealized gains during 2024 were $5,340,209 and $41,749,227 respectively.
    7. Reconciliation of Financial Statements to Form 5500
        The following is a reconciliation of net assets available for benefits per the financial statements to the Form 5500:
    December 31,
    20242023
    Net assets available for benefits per the financial statements
    $540,492,947 $500,054,550 
    Amounts allocated to withdrawing participants
    (417,535)(573,438)
    Net assets available for benefits per the Form 5500
    $540,075,412 $499,481,112 
    The following is a reconciliation of the net increase in net assets available for benefits per the financial statements to the Form 5500:
    December 31, 2024
    Net increase in net assets available for benefits per the financial statements
    $40,438,397 
    Less: Amounts allocated to withdrawing participants at December 31, 2024 (not yet paid)
    (417,535)
    Add: amounts allocated to withdrawing participants at December 31, 2023
    573,438 
    Net increase in net assets available for benefits per the Form 5500
    $40,594,300 
    12

    Johnson & Johnson Retirement Savings Plan
    Notes to Financial Statements

    8.    Subsequent Events

    The Plan has assessed subsequent events through the date that the financial statements were available to be issued and has determined that no other items require disclosure.

    13

    Johnson & Johnson Retirement Savings Plan
    Notes to Financial Statements





    Identity of Issue, Borrower,
    Lessor, or Similar Party
    Description of Investment
    Including Maturity Date, Rate of
    Interest, Collateral, Par or
    Maturity Value
    Cost
    Current Value
    Plan's interest in the Trust
    Plan's interest in the Johnson & Johnson Pension and Savings Plans Master Trust
    **
    $540,439,280 
    *Participant loans
    Interest rate of 3.25%. Matured in 2017 and 2020.
    **
    $1,524 


        *    Represents party-in-interest transactions
        **    Not applicable



    14
    Get the next $JNJ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNJ

    DatePrice TargetRatingAnalyst
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    12/10/2024$166.00Neutral
    BofA Securities
    11/15/2024$190.00Outperform
    Wolfe Research
    7/23/2024$160.00 → $150.00Outperform → Neutral
    Daiwa Securities
    5/30/2024$160.00Neutral
    Goldman
    4/18/2024$170.00Hold → Buy
    HSBC Securities
    12/13/2023$170.00 → $163.00Overweight → Equal Weight
    Wells Fargo
    12/1/2023$167.00 → $180.00Neutral → Buy
    UBS
    More analyst ratings

    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hewson Marillyn A

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      6/12/25 4:32:25 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Woods Eugene A.

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      6/12/25 4:30:37 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Innovative Medicine, R&D Reed John C converted options into 25,255 shares and covered exercise/tax liability with 11,002 shares, increasing direct ownership by 92% to 29,795 units (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      5/5/25 5:10:14 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    SEC Filings

    See more
    • SEC Form 11-K filed by Johnson & Johnson

      11-K - JOHNSON & JOHNSON (0000200406) (Filer)

      6/23/25 9:42:57 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Johnson & Johnson

      11-K - JOHNSON & JOHNSON (0000200406) (Filer)

      6/23/25 9:41:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - JOHNSON & JOHNSON (0000200406) (Filer)

      6/10/25 5:06:51 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC)

      The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG IMAAVY, an FcRn blocker, received U.S. FDA approval earlier this year for the broadest population of individuals living with gMG, including anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older SPRING HOUSE, Pa., June 23, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from an indirect treatment comparison (ITC) that showed consistent and sustained disease control with IMAAVY™ (nipocalimab-aahu) versu

      6/23/25 7:32:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Hit With $8M Verdict in Massachusetts Mesothelioma Talc Lawsuit

      Jury concludes J&J concealed the danger of its asbestos-laced talcum powder that caused woman's cancer A Suffolk County jury has awarded $8 million in favor of Janice Paluzzi, a Massachusetts woman who developed mesothelioma after decades of using Johnson & Johnson's (NYSE:JNJ) talcum powder products. The jury found the pharmaceutical giant liable for negligence and breach of warranty, concluding that the company's asbestos-contaminated talcum powder products caused Paluzzi's terminal cancer. During the trial, the Dean Omar Branham Shirley legal team, which represented Ms. Paluzzi, presented extensive evidence showing that Johnson & Johnson had internal knowledge of asbestos in its ta

      6/18/25 6:43:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma

      Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose  MILAN, June 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have not been previously treated with CAR T-cell therapy.1 Findin

      6/13/25 11:00:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

      5/13/25 8:56:13 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities resumed coverage on Johnson & Johnson with a new price target

      BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00

      12/10/24 8:28:42 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Johnson & Johnson with a new price target

      Wolfe Research initiated coverage of Johnson & Johnson with a rating of Outperform and set a new price target of $190.00

      11/15/24 8:10:35 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Leadership Updates

    Live Leadership Updates

    See more
    • Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors

      Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno

      6/10/25 4:51:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan

      WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines

      3/25/25 1:11:06 PM ET
      $JNJ
      $TVGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations

      Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. The new appointments are effective May 1, 2025, and Mr. Snellgrove as well as Ms. Moore, will continue to report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph Wolk. "Today's announcement reflects the deep bench of talent within Johnson & Johnson as well

      3/4/25 4:15:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Financials

    Live finance-specific insights

    See more
    • Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results

      Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o

      5/28/25 4:43:00 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Announces 63rd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.8%

      Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a 4.8% increase in the quarterly dividend, from $1.24 per share to $1.30 per share, marking the 63rd year of consecutive increases. At the new rate, the indicated dividend on an annual basis is $5.20 per share compared to the previous rate of $4.96 per share. The next quarterly dividend is payable on June 10, 2025 to shareholders of record at the close of business on May 27, 2025. The ex-dividend date is May 27, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, trea

      4/15/25 6:25:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Reports Q1 2025 Results

      2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn's disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the

      4/15/25 6:20:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Johnson & Johnson

      SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

      4/10/24 5:12:55 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      2/13/24 5:07:58 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Johnson & Johnson (Amendment)

      SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)

      1/30/24 12:46:49 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care